Research programme: topoisomerase II inhibitors - Reata PharmaceuticalsAlternative Names: Doxorubicin analogues - Reata; Reata 769; RTA 769; WP769
Latest Information Update: 12 Oct 2015
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Reata Pharmaceuticals
- Mechanism of Action Apoptosis stimulants; Type II DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Brain cancer; Cancer